Bristol Myers SquibbBMYEarnings & Financial Report
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...
BMY Q4 2025 Key Financial Metrics
売上高
$12.5B
粗利益
$8.4B
営業利益
N/A
純利益
$1.1B
粗利益率
67.2%
営業利益率
N/A
純利益率
8.7%
前年比成長
1.3%
EPS
$0.54
資金フロー
Bristol Myers Squibb Q4 2025 Financial Summary
Bristol Myers Squibb reported revenue of $12.5B for Q4 2025, with a net profit of $1.1B (8.7% margin). Cost of goods sold was $4.1B, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $12.5B |
|---|---|
| Net Profit | $1.1B |
| Gross Margin | 67.2% |
| Operating Margin | N/A |
| Report Period | Q4 2025 |
Bristol Myers Squibb Annual Revenue by Year
Bristol Myers Squibb annual revenue history includes year-by-year totals (for example, 2025 revenue was $48.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $48.2B |
| 2024 | $48.3B |
| 2023 | $45.0B |
| 2022 | $46.2B |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $11.87B | $12.20B | $11.89B | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B |
| 前年比成長 | 4.7% | 8.7% | 8.4% | 7.5% | -5.6% | 0.6% | 2.8% | 1.3% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $99.03B | $94.65B | $93.67B | $92.60B | $92.43B | $94.68B | $96.89B | $90.04B |
| 総負債 | $82.48B | $77.58B | $76.47B | $76.22B | $74.98B | $77.19B | $78.29B | $71.53B |
| 株主資本 | $16.49B | $17.02B | $17.14B | $16.34B | $17.39B | $17.43B | $18.55B | $18.47B |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $2.83B | $2.33B | $5.59B | $4.44B | $1.95B | $3.92B | $6.31B | $1.97B |
Other Health Care Companies
JNJ
Johnson & Johnson
売上高
$24.6B
純利益
$5.1B
LLY
Lilly (Eli)
売上高
$19.3B
純利益
$6.6B
MRK
Merck & Co.
売上高
$17.3B
純利益
$5.8B
PFE
Pfizer
売上高
$16.7B
純利益
$3.5B
VTRS
Viatris
売上高
$3.7B
純利益
N/A
ZTS
Zoetis
売上高
$2.4B
純利益
$603.0M
ABT
Abbott Laboratories
売上高
$11.4B
純利益
$1.6B
ABBV
AbbVie
売上高
$15.8B
純利益
$186.0M
A
Agilent Technologies
売上高
$1.9B
純利益
$434.0M
ALGN
Align Technology
売上高
$995.7M
純利益
$56.8M